On the HCPLive Hepatitis C page, resources on the topics of medical news and expert insight into HCV can be found. Content includes articles, interviews, videos, podcasts, and breaking news on hepatitis C virus research, treatment, and drug development.
July 3rd 2024
Emergency department admissions were linked to not receiving hepatitis C care among hospitalized patients who inject drugs or are living with hepatitis C.
FDA Grants Faster Review for Gilead's Hepatitis C New Drug Application
January 6th 2016The US Food and Drug Administration has granted Gilead Sciences priority review of a New Drug Application that seeks approval of its combination drug to treat all genotypes of chronic hepatitis C infection, the company announced.
Geographic Access Issues with Liver Transplantation
December 31st 2015The MELD (Model for End-stage Liver Disease) scoring system was developed to decrease access disparity for patients who need a liver transplant. Despite its implementation, large geographic disparities exist in the likelihood of either being removed from the transplant list due to progressive disease or actually receiving a transplant.
Egyptian Program May Be Roadmap for Treating Large Populations of HCV Patients
A public health experiment in which the Egyptian government has obtained large quantities of sofosbuvir for much less than its retail price is impacting the lives of tens of thousands of people.
Hep C Drugs: Prices to Plummet, but Not in US
The much-criticized high prices of directing-acting antivirals for hepatitis C are headed for a plunge -- but not in the US. Much as they did with HIV drugs years ago, pharma companies are giving away patents in many poor nations. Prices in the US will likely not change much.
Tasmanian Physicians Find Less Expensive Route to Obtaining Hepatitis C Medications
Physicians and patients in Tasmania are finding creative ways to get around the high cost of drugs to treat the hepatitis C virus. The group is importing the medications in powdered form or as tablets, from countries like India, Bangladesh and China, where patents for the drug does not exist.
Senate Finance Committee Criticizes Gilead's Hepatitis C Drug Pricing
A report released by Senator Ron Wyden (D-OH) and Charles Grassley (R-IA) came to the conclusion that Gilead Sciences charged more for its blockbuster hepatitis C virus medications Sovaldi and Harvoni than required to recoup acquisition costs, clinical research, and marketing expenditures.
CDC: Suburban, Rural Addicts Aren't Getting Enough Clean Needles
Injection drug users who reuse or share syringes spread hepatitis C and HIV. About half of these users live outside the cities, but there are relatively few needle exchange programs available to them, according to the CDC.
Study Probes Value of Hepatitis C Treatment at All Stages of Liver Fibrosis
December 9th 2015Treating hepatitis C sooner rather than later -- even at the early stages of liver fibrosis -- is worth the thousands of dollars it costs to pay for the new, more effective drugs, according to researchers who developed a model to assess historical treatment data.
Senate Probe Slams Drug Maker for Jacking Up Price of Hepatitis C Pill
December 3rd 2015A US Senate investigation found that drug maker Gilead Sciences sought to maximize profits of its blockbuster hepatitis C drug, without any significant consideration of the thousands of patients who could not afford its pricey pill.
PCORI Awards $14 Million Grant for Study of Hepatitis C Among Drug Users
The Patient-Centered Outcomes Research Institute (PCORI) has awarded a $14 million grant to a research team at Montefiore Health System and Albert Einstein College of Medicine to determine how best to treat hepatitis C virus (HCV) among people who have used injectable drugs.
Hepatologists around the world are seeing an influx of patients with various liver conditions including non-alcoholic fatty liver disease. Finding ways to treat these patients has become a growing area of the field. These issues are the same whether doctors are treating military patients or those in civilian practice alike.
Q&A With Sophie Megnien From Genfit: Work Progressing On New Nonalcoholic Steatohepatitis Treatment
While there are currently no approved treatments for nonalcoholic steatoheptitis there are medications working their way through the approval process including at least a few in phase III studies.
When teenage boys in Sweden were required to take part in the conscription process for the country's armed forces only a small percentage were considered overweight or obese. As a result researchers were able to make a connection between those patients and those who developed serious liver disease later in life.
Q&A With Jidong Jia From Beijing Friendship Hospital: Bringing New Hepatitis Medications To China
With a population of more than 1.4 million people it is important for patients to be treated as effectively as possible to help their own health as well as prevent their conditions from spreading. A new study looked at bringing help to hepatitis C patients in this growing country.
Hardcore Drug Use No Barrier to HCV Treatment
Due in part to the high prices direct-acting antivirals for hepatitis C infection, many Medicaid programs are not offering them to injection drug users, nor are some states and institutions seeking these patients out for testing to see if they have the virus. But a new study shows that even when drug-users do not give up their habit, they can be safely and effectively treated for the lethal virus.